| [1] |
李子禹, 季鑫, 季加孚. 新辅助化疗对胃癌手术并发症的影响[J]. 中国实用外科杂志, 2013, 33(4): 275-278.
|
| [2] |
Frei E 3rd. Clinical cancer research: An embattled species[J]. Cancer, 1982, 50(10): 1979-1992.
|
| [3] |
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J]. N Engl J Med, 2006, 355(1): 11-20.
|
| [4] |
中华人民共和国国家卫生健康委员会. 胃癌诊疗规范(2018) . 2018-12-21.
|
| [5] |
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology[M/OL]: Gastric Cancer. Ver 3. 2020.[2020-8-14]
URL
|
| [6] |
Yoshida K, Kazuya Y, Naoki O, et al. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification[J]. Gastric Cancer, 2016, 19(2): 329-338.
|
| [7] |
Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial[J]. Lancet Oncol, 2010, 11(5): 439-449.
|
| [8] |
Iwasaki Y, Sasako M, Yamamoto S, et al. Phase Ⅱ study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210)[J]. J Surg Oncol, 2013, 107(7): 741-745.
|
| [9] |
Terashima M, Iwasaki Y, Mizusawa J, et al. Randomized phase Ⅲ trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG 0501)[J]. Gastric Cancer, 2019, 22(5): 1044-1052.
|
| [10] |
Xiang X, Su Y, Li G, et al. Phase Ⅱ study of preoperative intra-arterial epirubicin, etoposide, and oxaliplatin combined with oral S-1 chemotherapy for the treatment of Borrmann type 4 gastric cancer[J]. J Gastric Cancer, 2020, 20(4): 395-407.
|
| [11] |
Ji J, Shen L, Li Z, et al. LBA42 Perioperative chemotherapy of oxaliplatin combined with S-1 (SOX) versus postoperative chemotherapy of SOX or oxaliplatin with capecitabine (XELOX) in locally advanced gastric adenocarcinoma with D2 gastrectomy: A randomized phase Ⅲ trial (RESOLVE trial)[J]. Ann Oncol, 2019, 30(Suppl 5): mdz394.033.
|
| [12] |
Wang X, Li S, Sun Y, et al. The protocol of a prospective, multicenter, randomized, controlled phase Ⅲ study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-Ⅱ trial[J]. BMC Cancer, 2021, 21(1): 20.
|
| [13] |
Sah BK, Zhang B, Zhang H, et al. Neoadjuvant FLOT versus SOX phase Ⅱ randomized clinical trial for patients with locally advanced gastric cancer[J]. Nat Commun, 2020, 11(1): 6093.
|
| [14] |
Wang J, Saukel GW, Garberoglio CA, et al. Pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen in gastric cancer: A case report[J]. J Hematol Oncol, 2010, 3: 31.
|
| [15] |
Wagner AD, Grabsch HI, Mauer M, et al. EORTC-1203-GITCG- the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: A randomized phase Ⅱ-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group[J]. BMC Cancer, 2019, 19(1): 494.
|
| [16] |
Silva ND, Schulz L, Paterson A, et al. Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma[J]. Br J Cancer, 2015, 113(9): 1305-1312.
|
| [17] |
Zheng Y, Yang X, Yan C, et al. Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase Ⅱ trial[J]. Eur J Cancer, 2020, 130: 12-19.
|
| [18] |
Matsui H, Shimizu Y, Tachikawa H, et al. Locally advanced gastric cancer responding to neoadjuvant chemotherapy with ramucirumab plus paclitaxel-case report[J]. Gan To Kagaku Ryoho, 2019, 46(10): 1565-1567.
|
| [19] |
Stahl M, Maderer A, Lordick F, et al. Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: randomized phase Ⅱ study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801)[J]. Eur J Cancer, 2018, 93: 119-126.
|
| [20] |
Moehler MH, Janjigian YY, Adenis A, et al. CheckMate 649: A randomized, multicenter, open-label, phase Ⅲ study of nivolumab (NIVO) + ipilimumab (IPI) or nivo + chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer [abstract] [J]. J Clin Oncol, 2018, 36(4 suppl): TPS192.
|
| [21] |
Bang YJ, Van Cutsem E, Fuchs CS, et al. KEYNOTE-585: phase Ⅲ study of perioperative chemotherapy with or without pembrolizumab for gastric cancer[J]. Future Oncol, 2019, 15(9): 943-952.
|
| [22] |
Chubenko V, Inusilaev G, Imyanitov E, et al. Clinical case of the neoadjuvant treatment with nivolumab in a patient with microsatellite unstable (MSI-H) locally advanced gastric cancer[J]. BMJ Case Rep, 2020, 13(9): e236144.
|
| [23] |
Liu L, Liu Y, Gong L, et al. Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: A case report and review of the literature[J]. Cancer Biol Ther, 2020, 21(11): 983-989.
|
| [24] |
Hu SB, Liu CH, Wang X, et al. Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer[J]. World J Surg Oncol, 2019, 17(1): 3.
|
| [25] |
Chen L, Yan Y, Zhu L, et al. Systemic immune-inflammation index as a useful prognostic indicator predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy[J]. Cancer Manag Res, 2017, 9: 849-867.
|
| [26] |
Gong W, Zhao L, Dong Z, et al. After neoadjuvant chemotherapy platelet/lymphocyte ratios negatively correlate with prognosis in gastric cancer patients[J]. J Clin Lab Anal, 2018, 32(5): e22364
|
| [27] |
Sun Z, Zhang N. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy[J]. World J Surg Oncol, 2014, 12: 397.
|
| [28] |
Tan B, Li Y, Di Y, et al. Clinical value of peripheral blood microRNA detection in evaluation of SOX regimen as neoadjuvant chemotherapy for gastric cancer[J]. J Clin Lab Anal, 2018, 32(4): e22363.
|
| [29] |
Gertsen EC, Jongh C, Brenkman HJF, et al. The additive value of restaging-CT during neoadjuvant chemotherapy for gastric cancer[J]. Eur J Surg Oncol, 2020, 46(7): 1247-1253.
|
| [30] |
Sun K, Hu H, Chen S, et al. CT-based radiomics scores predict response to neoadjuvant chemotherapy and survival in patients with gastric cancer[J]. BMC Cancer, 2020, 20(1): 468.
|
| [31] |
Zhu Y, Sun Y, Hu S, et al. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: A retrospective study of 192 cases from National Cancer Center in China[J]. BMC Gastroenterol, 2017, 17(1): 41.
|
| [32] |
Li Z, Wang Y, Ying X, et al. Different prognostic implication of ypTNM stage and pTNM stage for gastric cancer: A propensity score-matched analysis[J]. BMC Cancer, 2019, 19(1): 80.
|
| [33] |
Rawicz-Pruszyński K, Ciseł B, Mlak R, et al. The role of the lymph node ratio in advanced gastric cancer after neoadjuvant chemotherapy[J]. Cancers (Basel), 2019, 11(12): 1914.
|
| [34] |
Kumazu Y, Oba K, Hayashi T, et al. Relationship between the waiting times for surgery and survival in patients with gastric cancer[J].World J Surg, 2020, 44(4): 1209-1215.
|
| [35] |
Liu Y, Zhang KC, Huang XH, et al. Timing of surgery after neoadjuvant chemotherapy for gastric cancer: impact on outcomes[J]. World J Gastroenterol, 2018, 24(2): 257-265.
|
| [36] |
Feng D, Leong M, Li T, et al. Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy[J]. World J Surg Oncol, 2015, 13: 11.
|
| [37] |
Li Z, Shan F, Ying X, et al. Assessment of laparoscopic distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: A randomized clinical trial[J]. JAMA Surg, 2019, 154(12): 1093-1101.
|
| [38] |
Li Z, Shan F, Wang Y, et al. Laparoscopic versus open distal gastrectomy for locally advanced gastric cancer after neoadjuvant chemotherapy: safety and short-term oncologic results[J]. Surg Endosc, 2016, 30(10): 4265-4271.
|